A privacy-enhanced YouTube player (youtube-nocookie.com) that loads only when you click, wrapped in attribution: the channel, a link to the original, the length, the upload date and the date the video id was confirmed against YouTube. On its own page it shows the whole library grouped by playlist. Nothing is downloaded or rehosted.
Ohio State Wexner Medical Center · 1:27
A 90-second hospital explainer that gets the essentials right: GLP-1 agonists mimic a gut hormone, act on receptors in the brain and gastrointestinal tract, affect appetite and satiety as well as glucose, and semaglutide's cardiovascular benefit appears partly independent of weight loss.
Read the fact-checkHarvard Medical School Continuing Education · 6:32
A Brigham and Women's endocrinologist walks through the trials that established liraglutide and semaglutide for weight management: SCALE, STEP 1, STEP 8 and STEP 4, with the correct primary numbers for each.
Read the fact-checkSpeed Pharmacology · 17:16
A pharmacology educator's overview of every diabetes drug class, with a compact and accurate account of the incretin effect, DPP-4 degradation, and why GLP-1 mimetics slow gastric emptying, promote satiety and cause weight loss.
Read the fact-checkJohns Hopkins Medicine · 38:02
A 38-minute Johns Hopkins podcast with an obesity medicine physician: body composition and ageing, why lifestyle alone rarely holds more than 5 to 8 percent, GLP-1s as long-term therapy like a statin, what the first weeks feel like, and a candid answer on compounded products.
Read the fact-checkStanford Medicine · 3:15
A three-minute Stanford Medicine piece with several faculty: the class has been prescribed since 2005, the benefits reach the heart, kidneys, liver and sleep apnoea, the common side effects are gastrointestinal, and weight bias shapes how side effects are judged.
Read the fact-checkMayo Proceedings · 3:44
Two Mayo Clinic research fellows summarise their Mayo Clinic Proceedings paper: in adults with type 1 diabetes and overweight or obesity treated with tirzepatide, mean weight loss of 8.5 percent at a median 8 months and 12 percent at 12 months, a 1 percentage-point A1c fall and a 31.6 percent drop in insulin requirement.
Read the fact-checkEndocrine Society · 48:11
An Endocrine Society journal club on a JCEM metabolomics analysis of a 26-week phase 2 trial against dulaglutide and placebo: tirzepatide lowered branched-chain amino acids and their catabolites, 2-hydroxybutyrate and several triglyceride and diglyceride species in a dose-dependent way, changes that correlated with insulin-sensitivity markers.
Read the fact-checkCardiometabolic Health Congress (CMHC) · 16:44
Two clinical trialists discuss tirzepatide as it was in early 2023: SURPASS glycaemic results, SURMOUNT-1 weight loss, the 2.5 mg start and four-week steps, switching from a GLP-1, the oral contraceptive caution in the label and the absence of a cardiovascular outcomes trial at the time.
Read the fact-checkTaking Control Of Your Diabetes® · 7:45
Two endocrinologists from the nonprofit TCOYD compare tirzepatide and semaglutide category by category: A1c and weight favour tirzepatide in SURPASS-2, kidney and heart outcome data favour semaglutide, sleep apnoea favours tirzepatide, and both must be continued to keep the benefit.
Read the fact-checkNEJM Group · 2:17
NEJM's two-minute summary of SELECT: 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes, semaglutide 2.4 mg versus placebo, primary composite of cardiovascular death, non-fatal MI or non-fatal stroke in 6.5 versus 8.0 percent over a mean 39.8 months.
Read the fact-checkCleveland Clinic · 1:01
A one-minute Cleveland Clinic clip in which a SELECT investigator states the headline: a roughly 20 percent relative reduction in major cardiovascular events in people with prior cardiovascular disease and overweight or obesity without diabetes.
Read the fact-checkHarvard Medical School Continuing Education · 9:31
A Harvard Medical School teaching video on prescribing liraglutide and semaglutide for weight management: label indications, the medullary thyroid carcinoma and MEN 2 contraindication, pregnancy, gallbladder and pancreatitis cautions, retinopathy, gastroparesis, hypoglycaemia with insulin, injection sites, pen differences and the titration schedules.
Read the fact-checkCleveland Clinic · 45:05
A 45-minute Cleveland Clinic podcast with an endocrinologist: how the drugs suppress hunger and slow gastric emptying, expected weight loss by agent, why they are long-term therapy, GI side effects in roughly half of trial participants and more in practice, and the rarer risks.
Read the fact-checkNick Sterling, MD, PhD · 6:57
An emergency physician ranks the GLP-1 problems he sees: nausea and vomiting, dehydration progressing to acute kidney injury, starvation ketosis, muscle loss in people who are not strength training or eating enough protein, low mood, and gastroparesis as an honourable mention.
Read the fact-checkDr. Spencer Nadolsky · 12:16
An obesity medicine physician on nausea, constipation, reflux, diarrhoea and fatigue: nausea peaks early and fades, constipation persists, do not escalate until nausea is mild, avoid heavy fatty meals, hydrate, add fibre, and how his clinic uses antiemetics, laxatives and acid suppression when food changes are not enough.
Read the fact-checkAnesthesia Patient Safety Foundation (APSF) · 27:47
The Anesthesia Patient Safety Foundation podcast on retained gastric contents: two case reports despite standard fasting, the June 2023 ASA guidance to hold weekly agents one week and daily agents on the day before elective procedures, and gastric ultrasound as a bedside check.
Read the fact-checkEndocrine Society · 11:49
An Endocrine Society podcast with an NYU endocrinologist on compounded GLP-1s: what compounding is, why it was permitted during the shortage, the shortage end dates, that compounded products are not FDA approved, and the dosing confusion caused by units, millilitres and reconstitution.
Read the fact-checkStanford Health Care · 52:30
A Stanford Health Care dietitian's hour on GI side effects with trial ranges: nausea in about a quarter of participants at week four falling to about 15 percent by week eight and 5.5 percent by week 56, dose dependence across STEP, SUSTAIN, SCALE and LEAD, plus small frequent meals, less fat, more protein and liquids on bad days.
Read the fact-checkVeterans Health Administration · 5:48
The Veterans Health Administration's step-by-step vial-and-syringe demonstration: room temperature, hand washing, site choice and rotation, wiping the stopper, drawing air, injecting air into the vial, drawing the dose, clearing bubbles, pinching skin, a straight smooth insertion, a three-second hold and sharps disposal.
Read the fact-checkWeber State University · 4:36
A university nursing skills demonstration of insulin syringe handling: the units scale, injecting air before drawing, scrubbing multi-dose vial tops, a 45-degree subcutaneous angle, not hesitating on insertion, injecting slowly and going straight to the sharps container.
Read the fact-checkaphapharmacists · 4:06
The American Pharmacists Association's training clip on subcutaneous administration into the back of the upper arm: locating the site over the triceps, alcohol and drying, a 45-degree darting insertion, plunger technique, safety device, sharps and a post-injection check.
Read the fact-checkMayo Clinic · 1:00
A one-minute Mayo Clinic news piece: stopping within about six months carries a high chance of regain, appetite signals return to their default once the drug is gone, and any stop should be discussed with a clinician.
Read the fact-checkYale Medicine · 4:26
A Yale physician explains the defended fat-mass set point: obesity as a neurometabolic disease, why lifestyle loss is hard to hold, how nutrient-stimulated hormones inform the brain, and why medications and surgery work by acting on the mechanism rather than on willpower.
Read the fact-checkYale Medicine · 3:15
Yale clinicians on where medication fits: the set point again, incretin-based drugs imitating fullness hormones, the fact that every trial paired the drug with a calorie deficit and activity, the wide range of individual response, and combining medication with endoscopic procedures.
Read the fact-checkYale Medicine · 3:56
Yale's weight management team on lifestyle: intervention alone averages about 3 to 4 percent loss, diet means eating pattern rather than restriction, exercise is weaker for weight loss than medication or surgery but essential for maintenance and health, and sleep and mood matter.
Read the fact-checkStanford Health Care · 59:23
A Stanford Health Care clinical pharmacist's hour-long walk through the evidence: GLP-1 physiology, each agent and its dose steps, A1c and weight results from SUSTAIN, SUSTAIN FORTE, SURPASS and SURMOUNT, the SUSTAIN-6 and FLOW outcome trials, and the retinopathy caution with rapid glucose lowering.
Read the fact-checkUCSF Department of Medicine · 1:01:36
UCSF Department of Medicine grand rounds from the director of the UCSF weight management clinic: what percentage of loss improves which comorbidity, every FDA-approved anti-obesity medication with its one-year and two-year figures, GLP-1 pharmacology, side-effect rates, and the observation that women respond more strongly to tirzepatide in the SURMOUNT trials.
Read the fact-check27 videos across 6 playlists. Every one was confirmed against YouTube's oEmbed endpoint on the date shown on its page.
Assumptions, checked September 4, 2026
This calculator is an arithmetic aid for medication a licensed prescriber has already prescribed. It does not recommend a dose. Confirm any result with your prescriber or pharmacist before use.
Read before you use it
Nick Sterling, MD, PhD ranks what he sees in the emergency department: nausea and vomiting, dehydration and kidney injury, starvation ketosis, muscle loss and low mood. Useful clinical texture; not incidence data, and two sections lean on general evidence rather than GLP-1 trials.
Two Mayo research fellows summarise their retrospective study of tirzepatide in adults with type 1 diabetes and obesity. The numbers match the paper; the use is off-label and the study design limits what it can show.
The journal's own video abstract of semaglutide and cardiovascular outcomes in obesity. Every figure is from the paper; we add the ones a two-minute cut leaves out: hazard ratio, absolute difference, dropouts and what the trial does not show.
From the FormBlends network
Educational, not medical advice. Read the medical disclaimer.